First evaluation of the safety, pharmacokinetics, and pharmacodynamics of BAY 2433334, a small molecule targeting coagulation factor XIa

BACKGROUND: Coagulation factor XI (FXI) contributes to the development of thrombosis but appears to play a minor role in hemostasis and is, therefore, an attractive anticoagulant drug target. OBJECTIVES: To evaluate the safety, pharmacokinetic, and pharmacodynamic properties of BAY 2433334, an orall...

Descripción completa

Detalles Bibliográficos
Autores principales: Thomas, Dirk, Kanefendt, Friederike, Schwers, Stephan, Unger, Sigrun, Yassen, Ashraf, Boxnick, Stefanie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
HAEMOSTASIS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518835/
https://www.ncbi.nlm.nih.gov/pubmed/34192419
http://dx.doi.org/10.1111/jth.15439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8518835/
https://www.ncbi.nlm.nih.gov/pubmed/34192419
http://dx.doi.org/10.1111/jth.15439

Ejemplares similares